Literature DB >> 16325877

The vervet monkey (Chlorocebus aethiops) as an experimental model for Trypanosoma brucei gambiense human African trypanosomiasis: a clinical, biological and pathological study.

O Ouwe-Missi-Oukem-Boyer1, J Mezui-Me-Ndong, C Boda, I Lamine, F Labrousse, S Bisser, B Bouteille.   

Abstract

It has long been known that the vervet monkey, Chlorocebus (C.) aethiops, can be infected with Trypanosoma rhodesiense, but this model has not been described for T. gambiense. In this study, we report the development of such a model for human African trypanosomiasis. Twelve vervet monkeys infected with T. gambiense developed chronic disease. The duration of the disease ranged between 23 and 612 days (median 89 days) in five untreated animals. Trypanosomes were detected in the blood within the first 10 days post-infection and in the cerebrospinal fluid, with a median delay of 120 days (n = 4, range 28-348 days). Clinical changes included loss of weight, adenopathy, and in some cases eyelid oedema and lethargy. Haematological alterations included decreases in haemoglobin level and transitory decreases in platelet count. Biological modifications included increased gamma globulins and total proteins and decreased albumin. Pathological features of the infection were presence of Mott's cells, inflammatory infiltration of either mononuclear cells or lymphocytes and plasma cells in the brain parenchyma, and astrocytosis. These observations indicate that the development of the disease in vervet monkeys is similar to human T. gambiense infection. We conclude that C. aethiops is a promising experimental primate model for the study of T. gambiense trypanosomiasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16325877     DOI: 10.1016/j.trstmh.2005.07.023

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  7 in total

1.  A web-based brain atlas of the vervet monkey, Chlorocebus aethiops.

Authors:  Roger P Woods; Scott C Fears; Matthew J Jorgensen; Lynn A Fairbanks; Arthur W Toga; Nelson B Freimer
Journal:  Neuroimage       Date:  2010-10-13       Impact factor: 6.556

Review 2.  Vaccination against trypanosomiasis: can it be done or is the trypanosome truly the ultimate immune destroyer and escape artist?

Authors:  Florencia La Greca; Stefan Magez
Journal:  Hum Vaccin       Date:  2011-11

3.  Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeys.

Authors:  John K Thuita; Kristina K Wolf; Grace A Murilla; Arlene S Bridges; David W Boykin; James N Mutuku; Qiang Liu; Susan K Jones; Charles O Gem; Shelley Ching; Richard R Tidwell; Michael Z Wang; Mary F Paine; Reto Brun
Journal:  PLoS Negl Trop Dis       Date:  2015-02-05

Review 4.  To the Skin and Beyond: The Immune Response to African Trypanosomes as They Enter and Exit the Vertebrate Host.

Authors:  Omar A Alfituri; Juan F Quintana; Annette MacLeod; Paul Garside; Robert A Benson; James M Brewer; Neil A Mabbott; Liam J Morrison; Paul Capewell
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

Review 5.  Generation of neuroinflammation in human African trypanosomiasis.

Authors:  Jean Rodgers; Israel Steiner; Peter G E Kennedy
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-08-29

6.  In-vivo evaluation of a reinforced ovine biologic: a comparative study to available hernia mesh repair materials.

Authors:  N Overbeck; G M Nagvajara; S Ferzoco; B C H May; A Beierschmitt; S Qi
Journal:  Hernia       Date:  2020-01-31       Impact factor: 4.739

Review 7.  Research Relevant Conditions and Pathology in Nonhuman Primates.

Authors:  Chandra Saravanan; Thierry Flandre; Carolyn L Hodo; Anne D Lewis; Lars Mecklenburg; Annette Romeike; Oliver C Turner; Hsi-Yu Yen
Journal:  ILAR J       Date:  2020-12-31       Impact factor: 1.521

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.